Hearing Loss and Erythromycin Pharmacokinetics in a Patient Receiving Hemodialysis

Patricia D. Kroboth, Melissa A. McNeil, Arthur Kreeger, Jesus Dominguez, Raymond Rault

Research output: Contribution to journalArticle

29 Citations (Scopus)

Abstract

A left upper lobe pneumonia developed in a patient who was receiving hemodialysis; he was treated intravenously with 1 g of erythromycin lactobionate every six hours. After five doses, hearing loss was noted; this was later documented by audiogram. Erythromycin serum concentrations as high as 100 mg/L and a half-life more than three times longer than normal were observed. To our knowledge, this represents the first report of reversible hearing loss associated with elevated serum erythromycin concentrations and prolonged serum half-life.

Original languageEnglish (US)
Pages (from-to)1263-1265
Number of pages3
JournalArchives of Internal Medicine
Volume143
Issue number6
DOIs
StatePublished - 1983
Externally publishedYes

Fingerprint

Erythromycin
Hearing Loss
Renal Dialysis
Pharmacokinetics
Half-Life
Serum
Pneumonia

ASJC Scopus subject areas

  • Internal Medicine

Cite this

Hearing Loss and Erythromycin Pharmacokinetics in a Patient Receiving Hemodialysis. / Kroboth, Patricia D.; McNeil, Melissa A.; Kreeger, Arthur; Dominguez, Jesus; Rault, Raymond.

In: Archives of Internal Medicine, Vol. 143, No. 6, 1983, p. 1263-1265.

Research output: Contribution to journalArticle

Kroboth, Patricia D. ; McNeil, Melissa A. ; Kreeger, Arthur ; Dominguez, Jesus ; Rault, Raymond. / Hearing Loss and Erythromycin Pharmacokinetics in a Patient Receiving Hemodialysis. In: Archives of Internal Medicine. 1983 ; Vol. 143, No. 6. pp. 1263-1265.
@article{c8fe48ea5b104001a2e69636e4f0fa12,
title = "Hearing Loss and Erythromycin Pharmacokinetics in a Patient Receiving Hemodialysis",
abstract = "A left upper lobe pneumonia developed in a patient who was receiving hemodialysis; he was treated intravenously with 1 g of erythromycin lactobionate every six hours. After five doses, hearing loss was noted; this was later documented by audiogram. Erythromycin serum concentrations as high as 100 mg/L and a half-life more than three times longer than normal were observed. To our knowledge, this represents the first report of reversible hearing loss associated with elevated serum erythromycin concentrations and prolonged serum half-life.",
author = "Kroboth, {Patricia D.} and McNeil, {Melissa A.} and Arthur Kreeger and Jesus Dominguez and Raymond Rault",
year = "1983",
doi = "10.1001/archinte.1983.00350060195035",
language = "English (US)",
volume = "143",
pages = "1263--1265",
journal = "JAMA Internal Medicine",
issn = "2168-6106",
publisher = "American Medical Association",
number = "6",

}

TY - JOUR

T1 - Hearing Loss and Erythromycin Pharmacokinetics in a Patient Receiving Hemodialysis

AU - Kroboth, Patricia D.

AU - McNeil, Melissa A.

AU - Kreeger, Arthur

AU - Dominguez, Jesus

AU - Rault, Raymond

PY - 1983

Y1 - 1983

N2 - A left upper lobe pneumonia developed in a patient who was receiving hemodialysis; he was treated intravenously with 1 g of erythromycin lactobionate every six hours. After five doses, hearing loss was noted; this was later documented by audiogram. Erythromycin serum concentrations as high as 100 mg/L and a half-life more than three times longer than normal were observed. To our knowledge, this represents the first report of reversible hearing loss associated with elevated serum erythromycin concentrations and prolonged serum half-life.

AB - A left upper lobe pneumonia developed in a patient who was receiving hemodialysis; he was treated intravenously with 1 g of erythromycin lactobionate every six hours. After five doses, hearing loss was noted; this was later documented by audiogram. Erythromycin serum concentrations as high as 100 mg/L and a half-life more than three times longer than normal were observed. To our knowledge, this represents the first report of reversible hearing loss associated with elevated serum erythromycin concentrations and prolonged serum half-life.

UR - http://www.scopus.com/inward/record.url?scp=84948721708&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84948721708&partnerID=8YFLogxK

U2 - 10.1001/archinte.1983.00350060195035

DO - 10.1001/archinte.1983.00350060195035

M3 - Article

VL - 143

SP - 1263

EP - 1265

JO - JAMA Internal Medicine

JF - JAMA Internal Medicine

SN - 2168-6106

IS - 6

ER -